Jasmine Zain, MD, emphasized the importance of good patient counseling when outlining the potential risks of secondary T-cell malignancies following CAR T-cell therapy.
|Poll|February 11, 2016
Posterior Mediastinal Mass Found in 47-Year-Old Patient
Author(s)Cesar A. Moran, MD
A 47-year-old woman presents with a posterior mediastinal mass, and a biopsy is performed. What is your diagnosis?
Advertisement
Advertisement
Related to this article
Misako Nagasaka, MD, PhD, discusses PALOMA-2’s 70% 3-year survival rate compared with historical MARIPOSA data for intravenous amivantamab.
Adult T-cell lymphoma and leukemia may warrant upfront allogeneic transplant, according to Mary Jo Lechowicz, MD.
Poster presentations at SOHO 2026 may inform multiple myeloma practice across the newly diagnosed and relapsed/refractory settings.
The IND clearance for IASO208, a CD20-targeted in vivo CAR-T therapy requiring no leukapheresis or lymphodepletion, enables advancement of a phase 1b trial.
The OMNI-EGFR inhibitor BH-30643 produced a 45% objective response rate among patients with EGFR C797S–positive disease in the phase 1/2 SOLARA trial.
Data presented at WCLC 2026 support the use of B7-H3–directed antibody drug conjugates and brain MRI surveillance in small cell lung cancer.
Amir T. Fathi, MD, explains which AML subgroups were excluded from PARADIGM and why chemotherapy remains standard for them.
Advertisement
Advertisement
Trending on CancerNetwork
1
Trastuzumab Botidotin Prolongs PFS vs T-DM1 in HER2+ Advanced Breast Cancer
2
Daraxonrasib Receives FDA Breakthrough Therapy Status in 1L Metastatic PDAC
3
IASO208 Receives FDA IND Clearance for Relapsed/Refractory B-Cell Lymphoma
4
How Does Azacitidine/Venetoclax Impact Hospital Burden in AML?
5